Viridian Therapeutics, Inc. (VRDN)
| Market Cap | 2.72B +83.7% |
| Revenue (ttm) | 71.13M +23,220.3% |
| Net Income | -334.03M |
| EPS | -3.46 |
| Shares Out | 113.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,131,047 |
| Open | 24.35 |
| Previous Close | 24.29 |
| Day's Range | 24.00 - 24.39 |
| 52-Week Range | 13.18 - 34.29 |
| Beta | 0.94 |
| Analysts | Strong Buy |
| Price Target | 36.63 (+52.5%) |
| Earnings Date | Aug 6, 2026 |
About VRDN
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves’ disease and TED. Its portfolio of engineered inhibitors o... [Read more]
Financial Performance
In 2025, Viridian Therapeutics's revenue was $70.85 million, an increase of 23359.93% compared to the previous year's $302,000. Losses were -$281.93 million, 35.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for VRDN stock is "Strong Buy." The 12-month stock price target is $36.63, which is an increase of 52.50% from the latest price.
News
Viridian Therapeutics price target raised to $39 from $38 at Truist
Truist raised the firm’s price target on Viridian Therapeutics (VRDN) to $39 from $38 and keeps a Buy rating on the shares.
Viridian Therapeutics price target raised to $36 from $35 at RBC Capital
RBC Capital analyst Lisa Walter raised the firm’s price target on Viridian Therapeutics (VRDN) to $36 from $35 and keeps an Outperform rating on the shares.
Viridian Therapeutics reports EPS ($1.05), consensus ($1.03)
Reports revenue $284,000 vs. $75,000 last year”We are very encouraged by the early indications from our recent launch of Lumvoa as we start a new chapter for Viridian as a…
Viridian Therapeutics sees cash runway through profitability
Cash, cash equivalents, and marketable securities were $981.5 million as of June 30, 2026, compared with $762.2 million as of March 31, 2026. Existing cash and anticipated future commercial revenues…
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for aut...
Viridian Therapeutics Earnings release: Q2 2026
Viridian Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Viridian Therapeutics Slides: Q2 2026
Viridian Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Viridian Therapeutics Quarterly report: Q2 2026
Viridian Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Viridian Therapeutics price target raised to $43 from $32 at Wedbush
Wedbush analyst Laura Chico raised the firm’s price target on Viridian Therapeutics (VRDN) to $43 from $32 and keeps an Outperform rating on the shares. Most notable on the Viridian…
Viridian Therapeutics price target raised to $38 from $35 at Truist
Truist raised the firm’s price target on Viridian Therapeutics (VRDN) to $38 from $35 and keeps a Buy rating on the shares. Viridian highlighted on its Lumvoa approval call a…
Viridian Therapeutics price target raised to $35 from $34 at RBC Capital
RBC Capital raised the firm’s price target on Viridian Therapeutics (VRDN) to $35 from $34 and keeps an Outperform rating on the shares. Viridian recently received FDA approval for Lumvoa…
Viridian Therapeutics price target raised to $39 from $35 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Viridian Therapeutics (VRDN) to $39 from $35 and keeps a Buy rating on the shares. Viridian highlighted on its FDA approval call…
Wells upgrades Viridian Therapeutics as Lumvoa launch KPIs likely to outperform
As previously reported, Wells Fargo analyst Derek Archila upgraded Viridian Therapeutics (VRDN) to Overweight from Equal Weight with a price target of $31, up from $20. The firm is getting…
Viridian Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
Wells Fargo upgraded Viridian Therapeutics (VRDN) to Overweight from Equal Weight with a price target of $31, up from $20.
Viridian Therapeutics Transcript: FDA announcement
Lumvoa received FDA approval as the first TED therapy with data for both active and chronic disease, offering rapid, durable symptom relief in a short 12-week regimen. Launch efforts focus on core prescribers, broad payer access, and patient support, with critical mass expected in 6–9 months.
Viridian Therapeutics Press release: FDA announcement
Viridian Therapeutics issued a press release on June 29, 2026, disclosing material business information to investors.
Viridian Therapeutics Slides: FDA announcement
Viridian Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 29, 2026.
Viridian Therapeutics announces FDA approval, launch of Lumvoa
Viridian Therapeutics (VRDN) announced that the U.S. FDA has approved Lumvoa for the treatment of thyroid eye disease. TED is a rare, debilitating autoimmune disease characterized by inflammation and ...
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for aut...
Viridian Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Commercial approval is expected by June 30, with full operational readiness and a trained sales force targeting 2,000 core prescribers. Differentiated clinical data and subcutaneous options position the portfolio for broad adoption in both active and chronic thyroid eye disease.
Viridian Metals Commences 2026 Diamond Drill Program at the Kraken
OTTAWA, June 09, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Company”) announces that diamond drilling has commenced at its Kraken Copper-Nickel-Cobalt Project in Lab...
Viridian Metals Highlights Copper-Rich Zones up to 4.15% Cu at Kraken Ahead of 2026 Drill Program
OTTAWA, Ontario, June 05, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Company”) is advancing plans to target high-grade copper-rich zones identified within the Kraken...
Viridian Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Advancing TED therapies with a PDUFA date in June 2026, the company is ready for commercial launch and expects strong market expansion with IV and subQ options. Financially robust, it targets broad access and sees significant opportunity in both active and chronic TED.
Viridian Therapeutics Slides: Company presentation
Viridian Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Viridian Therapeutics Slides: Corporate presentation
Viridian Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.